Charles River is expanding our team. Some of our exciting careers include:
I need a Charles River expert for technical assistance, customer service or sales support.
*indicates a required field.
The information you provided will be kept confidential.
juil. 29
Charles River Laboratories International, Inc. (NYSE: CRL), a leading global provider of research models and associated services and of preclinical drug development services, today announced that it has mutually agreed with WuXi PharmaTech (Cayman) Inc. (NYSE: WX) to terminate their previously announced acquisition agreement. The Company also announced that its Board of Directors has authorized a new $500 million stock repurchase program.
juil. 21
When animals are used in research, the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International works with institutions and researchers to serve as a bridge between progress and animal well-being. This coordination is accomplished through the voluntary AAALAC accreditation and assessment process, in which organizations demonstrate that they not only meet the minimum standards required by law, but also go the extra step to achieve excellence in animal care and use. Recently, the Charles River facility in Margate, UK, which breeds research models and provides related services, received full AAALAC accreditation. Charles River is the first and only commercial small animal breeder in the UK to receive AAALAC accreditation.
juil. 13
Genetic toxicology testing is a key element in the development of pharmaceuticals, agrochemicals and chemicals. Formal GLP testing is required as part of the safety evaluation of all compounds; however, many companies perform non-GLP genetic toxicology screening very early to avoid expensive failures later. At this point, compound availability is normally limited, so it is important to minimize usage while ensuring the most accurate predictivity of the outcome of the eventual GLP assays. Charles River now offers in vitro genetic toxicology screening assays in which compound requirements can be as little as 10 mg: Bluescreen HC, Bluescreen HC S9 and µAmes.
sept. 13–sept. 15
The Biotech symposium is designed to provide insights into nonclinical development of biologics. Specific topics that will be covered include: Safety Pharmacology of Therapeutic Proteins; Impact of Immunomodulatory Agents on Host Resistance; New Paradigms for Predicting Cancer Risks Posed by Immunosuppressive Drugs; PK/PD Modeling: Extrapolating from Animal Data into First-in-Human Dose; and DART Programs for Biotherapeutics: Study Designs, Challenges and Regulatory Influences. In addition to the symposium, we will offer a workshop on endemic diseases and micro-flora as they relate to toxicology on September 12th.
We are looking for a Pathologist at Charles River Montreal. This position will be responsible for overseeing necropsy, perfoming histopathological examinations, authoring pathology reports, providing pathology expertise to multidisciplinary teams, and communicating results with sponsors.
This position will be responsible for, among other things, developing short- and long-range marketing and sales objectives, strategies and tactics required to meet the business’ growth and profitability in all customer segments; leading the Clinical Specialist Sales Team in the value selling proposal and adapting an integrated solution sale to their product line; coordinating the Clinical Specialist Sales Team’s regular interface and communication with the Sales Team to relay shared goals, develop co-strategies to achieve defined targets and work cohesively as a team to provide excellence in service to clients; key account development; creating, maintaining and executing a marketing plan; and collaborating with corporate marketing to identify customer outsourcing needs.
This position is responsible for providing oversight, technical support and guidance to ensure that the company’s financial statements and records are prepared in accordance with company policy and Generally Accepted Accounting Principles; managing the global company consolidation on a monthly basis; ensuring corporate consolidation reconciliations are properly completed, reviewed and documented; gathering and reviewing monthly, quarterly and annual information for external reporting, audits, reviews and tax compliance; preparing and/or reviewing monthly income statement and balance sheet analysis for specific corporate and total company accounts; documenting and testing existing internal controls in support of Sarbanes-Oxley Section 404.